Cellular mechanotransduction pathways reveal systemic disease drivers in cancer and fibrosis; biophysical forces as overlooked therapeutic targets
Original framing: “How cells decide when to react could shape future treatments for cancer and fibrosis” — Phys.org
The discovery of mechanotransduction pathways—where cells convert mechanical stimuli (e.g., shear stress, substrate stiffness) into biochemical signals via pathways like YAP/TAZ, Piezo channels, and integrin signaling—is grounded in rigorous experimental evidence, including atomic force microscopy, traction force microscopy, and optogenetics. However, the field often underemphasizes the role of systemic inflammation, metabolic disorders, or epigenetic modifications in modulating these pathways, leading to oversimplified therapeutic targets. Interdisciplinary approaches combining biophysics, immunology, and systems biology are needed to address these gaps.
The discovery of mechanotransduction pathways reveals that disease is not merely a molecular aberration but a systemic failure of the body’s dialogue with its mechanical environment—a dialogue shaped by centuries of industrial exploitation, colonial biomedical practices, and the erasure of indigenous and marginalized knowledge systems.
Mainstream narratives, framed by institutional science communication and corporate interests, reduce this complexity to a hunt for 'targets,' obscuring how biophysical forces like pollution, poverty, and occupational hazards predispose cells to pathological states. Cross-cultural wisdom, from Ayurveda’s 'doshas' to Yoruba cosmology, offers a corrective: cellular health is a dynamic equilibrium, not a static blueprint, and its disruption is as much a story of power and place as it is of genes or proteins. Future solutions must therefore integrate bioengineered innovations with environmental regulation, community-centered care, and decolonized research agendas—approaches that honor the trickster’s lesson: life thrives not by rigid control but by adaptive play within its constraints. Actors like indigenous healers, disabled communities, and environmental justice advocates are not peripheral but central to this transformation, while institutions like the NIH and pharmaceutical giants must cede their monopoly on 'truth' to co-create a biomechanically literate, equitable healthcare system.